Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cetuximab in combination with encorafenib and binimetinib as induction therapy for BRAF V600E-mutated MSS colorectal cancer that is ini…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• BRAFTOVI (ENCORAFENIB)
• ERBITUX (cetuximab)
• MEKTOVI (BINIMETINIB)

Snippet

Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | Conditions: Colorectal Cancer | Phase 2 | Status: RECRUITING